E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Anaemia in patients with chronic kidney disease not on dialysis (pre-dialysis patients). |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the range of monthly (i.e., Q4W, every 4 weeks) doses of AF37702 Injection administered subcutaneously that increases and maintains hemoglobin at 11-13 g/dL in Chronic Kidney Disease (CKD) patients not on dialysis (pre-dialysis patients). |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the safety profile of up to six doses of AF37702 Injection administered subcutaneously on a Q4W schedule in pre-dialysis patients.
To evaluate the pharmacokinetic profiles of up to six doses of AF37702 Injection administered subcutaneously on a Q4W schedule in pre-dialysis patients (in a subset of study patients).
To evaluate the safety and pharmacodynamic profiles of up to six doses of AF37702 Injection administered intravenously on a Q4W schedule in pre-dialysis patients, with pharmacokinetic profiles in a subset of these patients.
To evaluate the safety and pharmacodynamic profiles of AF37702 Injection administered subcutaneously once every two weeks (Q2W) for up to 12 doses, with pharmacokinetic profiles in a subset of these patients. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The subject has signed a written, witnessed informed consent. Males or females, including women of childbearing potential on a highly effective method of birth control, age 18 - 85 years. GFR of ≤ 60 mL/min. Hemoglobin ≥ 9.0 and < 11.0 g/dL, serum ferritin ≥100 μg/L and transferrin saturation ≥ 20%, serum or red cell folate and vitamin B12 levels above the lower limits of normal, weight ≥ 45 kg, WBC ≥ 3.0 x10^9/L, platelet count ≥ 100 x10^9/L. |
|
E.4 | Principal exclusion criteria |
Any previous exposure to investigational or commercially available erythropoiesis stimulating agents (ESAs) in the 12 weeks prior to study enrollment, prior treatment with Eprex, intolerance of any ESA. History of PRCA. RBC transfusion within 12 weeks. Hemoglobinopathy, hemolysis, inflammatory disease, CRP > 30 mg/L, significant infection, febrile illness, hyperparathyroidism, poorly controlled hypertension, epileptic seizures, CHF (NYHA Class IV). Significant medical diseases or conditions, including history of MI, coronary artery disease, stroke, respiratory, autoimmune, neuropsychiatric or neurological abnormalities, liver disease, active HIV disease, significant history of multiple drug allergies, or other diseases within the past 6 months that may interfere with patient assessment. Malignancy within past 5 years, life-expectancy < 12 months, anticipated elective surgery, previous exposure to any investigational drug within prior 6 weeks or expected during the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Hemoglobin change from baseline at weekly intervals through Week 13 and at 2-week intervals through Week 25 • Proportion of patients per cohort with hemoglobin within 11-13 g/dL at Weeks 9, 13, 17, 21, and 25 • Proportion of patients per cohort achieving a Hgb response, defined as a Hgb increase of ≥ 1.0 g/dL from baseline and a Hgb ≥ 11.0 g/dL during the study • Number (%) of patients with no dose adjustments during the study and number (%) of patients with dose increase or decrease during the study • Incidence of red blood cell transfusions during the study • Pharmacologic parameters including RBCs, hematocrit, reticulocyte counts, reticulocyte hemoglobin content, and serum measures of iron status (e.g., serum ferritin, transferrin saturation, and transferrin receptor protein) • Adverse events (AEs) • Serious adverse events (SAEs) • Pharmacokinetic parameters including Cmax, AUC0-t, AUC0-∞, t½ß, Vd, Vss, and CL (in a subset of patients) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |